Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724520 | 0.87 | KCNH2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL170454 | 0.82 | NFE2L2 (0.41) | PPARGPPARANFE2L2CES2CES1 | |
| SCHEMBL26179618 | 0.79 | MRGPRX4 (0.46) | ESR2MRGPRX4 | |
| SCHEMBL1689762 | 0.77 | NFE2L2 (0.59) | NFE2L2CES2CES1MAOBACHE | |
| SCHEMBL3439551 | 0.77 | CA12 (0.39) | CES2CES1 | |
| SCHEMBL11955396 | 0.76 | CYP3A4 (0.48) | ESR2ESR1ACHE | |
| SCHEMBL14649506 | 0.75 | ENPP2 (0.60) | — | |
| SCHEMBL28287503 | 0.75 | NFE2L2 (0.37) | PPARGPPARANFE2L2ESR2SLC6A2 | |
| SCHEMBL6204387 | 0.75 | — | — | |
| SCHEMBL16547240 | 0.74 | SLC6A2 (0.39) | CES2CES1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024536-B2 | C-terminal HSP90 inhibitors | UNIVERSITY OF KANSAS (US) | 2024-07-02 | — | — | US | disclosed |
| US-11858952-B2 | Compound and color conversion film comprising same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| WO-2021132486-A1 | LAYERED BODY | 日東電工株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021132487-A1 | SEALANT SHEET WITH RELEASE LINER | 日東電工株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021132485-A1 | SEALING METHOD | 日東電工株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-10030041-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9732097-B2 | Process for the synthesis of a phosphoinositide 3-kinase inhibitor | INCYTE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20110230517-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2280000-A1 | COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY | Shionogi&Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2011-01-27 | — | — | US | disclosed |
| US-20100137597-A1 | SYNTHESIS Of DIETHYLPHOSPHONATE | SCHERING CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-7687631-B2 | Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2046804-A1 | SYNTHESIS OF DIETHYL{ I5\" (3 -FLUOROPHENYL) -PYRIDINE-2-YL] METHYL} PHOSPHONATE USED IN THE SYNTHESIS OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008005348-A1 | SYNTHESIS OF DIETHYL{ I5' (3 -FLUOROPHENYL) -PYRIDINE-2-YL] METHYL} PHOSPHONATE USED IN THE SYNTHESIS OF HIMBACINE ANALOGS | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004449-A1 | Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate | TOPROL ACQUISITION LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, GBA1 | HPGD 818/4885PPARG 1027/4885PPARA 874/4885 |
| US-20080004449-A1 | Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate | F2, F2R, PTAFR | HPGD 2241/4885PPARG 1034/4885PPARA 378/4885 |
| US-20110230517-A1 | CALCIUM RECEPTOR MODULATING AGENTS | CASR, CALCR, CNR1 | HPGD 1273/4885PPARG 1338/4885PPARA 1559/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | HPGD 2026/4885PPARG 811/4885PPARA 930/4885 |
| US-20100137597-A1 | SYNTHESIS Of DIETHYLPHOSPHONATE | F2, PTAFR, TBXA2R | HPGD 1438/4885PPARG 990/4885PPARA 286/4885 |
| US-11858952-B2 | Compound and color conversion film comprising same | BLVRB, CDYL, CRY1 | HPGD 3359/4885PPARG 2487/4885PPARA 3304/4885 |
| US-10030041-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | HPGD 1901/4885PPARG 1538/4885PPARA 3047/4885 |
| US-12024536-B2 | C-terminal HSP90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | HPGD 1901/4885PPARG 1538/4885PPARA 3047/4885 |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | HPGD 1206/4885PPARG 862/4885PPARA 2046/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | HPGD 3049/4885PPARG 601/4885PPARA 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.